Gemcitabine in the treatment of soft tissue sarcomas

Onkologie

Volumn 27, Issue 2, 2004, Pages 180-186

  Bauer, S ^a   Seeber, S ^a   Schutte J ^a,b  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b MARIEN HOSPITAL DÜSSELDORF   (Germany)

Author keywords

Gemcitabine; Second line treatment; Soft tissue sarcoma, advanced; Third line treatment

Indexed keywords

CARBOPLATIN; CISPLATIN; CYTOSTATIC AGENT; DNA TOPOISOMERASE INHIBITOR; DOCETAXEL; GEMCITABINE; NAVELBINE; PACLITAXEL; PROTEIN TYROSINE KINASE INHIBITOR; TOPOTECAN;

ANGIOSARCOMA; CANCER CHEMOTHERAPY; CLINICAL TRIAL; DRUG SENSITIVITY; EPITHELIUM TUMOR; HISTOPATHOLOGY; HUMAN; MESENCHYMOMA; METASTASIS; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; REVIEW; SOFT TISSUE SARCOMA; UTERUS MYOMA;

ADULT; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS; DEOXYCYTIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MIDDLE AGED; SARCOMA; TREATMENT OUTCOME;

EID: 2442473289     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000076910     Document Type: Review

References (34)

1. Nielsen OS, Dombernowsky P, Mouridsen H, Crowther D, Verweij J, Buesa J, Steward W, Daugaard S, van Glabbeke M, Kirkpatrick A, Tursz T: High-dose epirubicin is not an alternative to standard-dose doxorubicin in the treatment of advanced soft tissue sarcomas. A study of the EORTC Soft Tissue and Bone Sarcoma Group. Br J Cancer 1998;78:1634-1639.
2. Le Cesne A, Antoine E, Spielmann M, Le Chevalier T, Brain E, Toussaint C, Janin N, Kayitalire L, Fontaine F, Genin J: High-dose ifosfamide: Circumvention of resistance to standard-dose ifosfamide in advanced soft tissue sarcomas. J Clin Oncol 1995;13:1600-1608.
3. Nielsen OS, Judson I, van Hoesel Q, le Cesne A, Keizer HJ, Blay JY, van Oosterom A, Radford JA, Svancarova L, Krzemienlecki K, Hermans C, van Glabbeke M, Oosterhuis JW, Verweij J: Effect of high-dose ifosfamide in advanced soft tissue sarcomas. A multicentre phase II study of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 2000;36:61-67.
4. Buesa JM, Mouridsen HT, van Oosterom AT, Verweij J, Wagener T, Steward W, Poveda A, Vestlev PM, Thomas D, Sylvester R: High-dose DTIC in advanced soft-tissue sarcomas in the adult. A phase II study of the EORTC Soft Tissue and Bone Sarcoma Group. Ann Oncol 1991;2:307-309.
5. Borden EC, Amato DA, Rosenbaum C, Enterline HT, Shiraki MJ, Creech RH, Lerner HJ, Carbone PP: Randomized comparison of three adriamycin regimens for metastatic soft tissue sarcomas. J Clin Oncol 1987;5:840-850.
6. Casper ES, Waltzman RJ, Schwartz GK, Sugarman A, Pfister D, Ilson D, Woodruff J, Leung D, Bertino Jr: Phase II trial of paclitaxel in patients with soft-tissue sarcoma. Cancer Invest 1998;16:442-446.
7. Fata F, O'Reilly E, Ilson D, Pfister D, Leffel D, Kelsen, DP, Schwartz GK, Casper ES: Paclitaxel in the treatment of patients with angiosarcoma of the scalp or face. Cancer 1999;86:20034-20037.
8. Pappo AS, Lyden E, Breneman J, Wiener E, Teot L, Meza J, Crist W, Vietti T: Up-front window trial of topotecan in previously untreated children and adolescents with metastatic rhabdomyosarcoma: An intergroup rhabdomyosarcoma study. J Clin Oncol 2001;19:213-219.
9. Delaloge S, Yovine A, Taamma A, Riofrio M, Brain E, Raymond E, Cottu P, Goldwasser F, Jimeno J, Misset JL, Marty M, Cvitkovic E: Ecteinascidin-743: A marine-derived compound in advanced, pre-treated sarcoma patients - preliminary evidence of activity. J Clin Oncol 2001;19:1248-1255.
10. Le Cesne A, Blay JY, Judson I, van Oosterom A, Verweij J, Radford J, Lorigan P, Rodenhuis S, Di Paola DE, van Glabbeke M, Jimeno J, Nielsen O: ET-743 is an active drug in adult soft-tissue sarcoma (STS): A STBSG-EORTC phase II trial. Proc Am Soc Clin Oncol 2001;20:353a.
11. Thomas D, Giordano TJ, Benjamin RS, Samuels BL, Priebat DA, Bacus SS, Baker LH: Gleevec therapy in c-KIT negative soft tissue sarcomas: A molecular rationale. Eur J of Cancer 2002;38(Suppl 7):176a.
12. Sachsenmaier C: Targeting protein kinases for tumor therapy. Onkologie 2002;24:346-355.
13. Maki RG, Awan RA, Dixon RH, Jhanwar S, Antonescu CR: Differential sensitivity to imatinib of 2 patients with metastatic sarcoma arising from dermatofibrosarcoma protuberans. Int J Cancer 2002;100:623-626.
14. Amodio A, Carpano S, Manfredi C, Del Monte G, Di Lauro L, Gionfra T, Conti F, Paoletti G, Lopez M: Gemcitabin in advanced stage soft tissue sarcoma: A phase II study. Clin Ter 1999;150:17-20.
15. Merimsky O, Meller I, Flusser G, Kollender Y, Issakov J, Weil-Ben-Arush M, Fenig E, Neuman G, Sapir D, Ariad S, Inbar M: Gemcitabine in soft tissue or bone sarcoma resistant to standard chemotherapy: A phase II study. Cancer Chemother Pharmacol 2000;45:177-181.
16. Blumgart L, Espat N, Fong Y, Jarnagin W: Limited activity and acceptable toxicity of gemcitabine in a phase II study of patients with advanced sarcomas: A mayo cancer center study. Proc Am Soc Clin Oncol 2000;19:50.
17. Samuels BL, Barbour L, Schiller D: Phase I study of low dose continuous infusion gemcitabine in sarcoma patients. Proc Am Soc Clin Oncol 2001;20:2935a.
18. Späth-Schwalbe E, Genvresse I, Koschuth A, Dietzmann A, Grunewald R, Possinger K: Phase II trial of gemcitabine in patients with pre-treated advanced soft tissue sarcomas. Anticancer Drugs 2000;11:325-329.
19. Okuno S, Edmonson J, Mahoney M, Buckner JC, Frytak S, Galanis E: Phase II trial of gemcitabine in advanced sarcomas. Cancer 2002;94:3225-3229.
20. Patel SR, Gandhi V, Jenkins J, Papadopolous N, Burgess MA, Plager C, Plunkett W, Benjamin RS: Phase II clinical investigation of gemcitabine in advanced soft tissue sarcomas and window evaluation of dose rate on gemcitabine triphosphate accumulation. J Clin Oncol 2001;19:3483-3489.
21. Gautam U, Hurley J, Silva O, Benedetto PW, Robles C: Gemcitabine: An active chemotherapeutic agent for angiosarcoma. Proc Am Soc Clin Oncol 2002;21:2931a.
22. Bauer S, Hartung J, Gauler T, Gocke P, Flasshove M, Nowrousian MR, Bojko P, Hense J, Seeber S, Schuette J: Gemcitabine-containing chemotherapy in the treatment of patients with advanced soft tissue sarcoma. Tumordiagn Ther 2002;23:219-224.
23. Svancarova L, Blay JY, Judson IR, van Hoesel QG, van Oosterom AT, le Cesne A, Keizer HJ, Hermans C, van Glabbeke M, Verweij J, Hogendoorn PC, Nielsen OS: Gemcitabine in advanced adult soft-tissue sarcomas. A phase II study of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 2002;38:556-559.
24. Okuno S, Ryan LM, Edmonson JH, Priebat DA, Blum RH: Phase II trial of gemcitabine in patients with advanced sarcomas. Cancer 2003;97:1969-1973.
25. Burton GV, Rankin C, Flaherty LE, Borden EC, Mills GM, Antman KH: Phase II trial of gemcitabine as first line chemotherapy in patients with metastatic or unresectable soft tissue sarcomas (STS). Proc Am Soc Clin Oncol 2003;22:3297a.
26. Georgoulias V, Kouroussis C, Androulakis N: Front-line treatment of advanced non-small-cell lung cancer with docetaxel and gemcitabine: A multicenter phase II trial. J Clin Oncol 1999;17:914-920.
27. Colterelli TJ, Germino JF, Shanabrook L, Eid J, Dipaola R, Rubin E, Musanti R, Hait W: A phase II trial of gemcitabine, paclitaxel and carboplatin in stage IVB soft tissue sarcoma. Proc Am Soc Clin Oncol 2001;20:2930a.
28. Hensley ML, Maki R, Venkatraman E, Geller G, Lovegren M, Aghajanian C, Sabbatini P, Tong W, Barakat R, Spriggs DR: Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: Results of a phase II trial. J Clin Oncol 2002;20:2824-2831.
29. Buesa JM, Fra J, Lopez-Pousa A, Losa R, Mareque B, Sierra M, Una E, Blay P: Phase I clinical trial of dacarbazine (DTIC) and prolonged infusion gemcitabine in patients with soft tissue sarcoma (STS). Proc Am Soc Clin Oncol 2002;21:3296a.
30. Steward WP, Verweij J, Somers R, Spooner D, Kerbrat P, Clavel M, Crowther D, Rouesse J, Tursz T, Tueni E: Granulocyte-macrophage colony-stimulating factor allows safe escalation of dose-intensity of chemotherapy in metastatic adult soft tissue sarcomas: A study of the EORTC Soft Tissue and Bone Sarcoma Group. J Clin Oncol 1993;11:1-2.
31. Le Cesne A, Judson I, Crowther D, Rodenhuis S, Keizer HJ, Van Hoesel Q, Blay JY, Frisch J, Van Glabbeke M, Hermans C, Van Oosterom A, Tursz T, Verweij J: Randomized phase III study comparing conventional-dose doxorubicin plus ifosfamide versus high-dose doxorubicin plus ifosfamide plus recombinant human granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: A trial of the European Organization for Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma Group. J Clin Oncol 2000;18:2676-2684.
32. Grunewald R, Abbruzzese JL, Tarassoff P, Plunkett W: Saturation of 2′,2′-difluorodeoxycytidine 5′-triphosphate accumulation by mononuclear cells during a phase I trial of gemcitabine. Cancer Chemother Pharmacol 1991;27:258-262.
33. Verweij J, Lee SM, Ruka W, Buesa J, Coleman R, van Hoesel R, Seynaeve C, di Paola ED, van Glabbeke M, Tonelli D, Judson I: Randomized phase II study of docetaxel versus doxorubicin in first- and second-line chemotherapy for locally advanced or metastatic soft tissue sarcomas in adults: A study of the European Organization for Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma Group. J Clin Oncol 2000;18:2081-2086.
34. van Glabbeke M, Verweij J, Judson I, Nielsen OS: Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas. Eur J Cancer 2002;38:543-549.